579474-49-0

Usage

Uses

Used in Pharmaceutical Research and Development:
(2-AMINO-4-CHLORO-PHENYL)-CARBAMIC ACID TERT-BUTYL ESTER is used as a building block for the synthesis of pharmaceutical compounds, contributing to the development of new drugs and materials. Its unique chemical properties make it a valuable asset in the creation of innovative therapeutic agents.
Used in Chemical Research:
In the field of chemical research, (2-AMINO-4-CHLORO-PHENYL)-CARBAMIC ACID TERT-BUTYL ESTER is employed to study the structure-activity relationships of specific chemical compounds. This helps in understanding how the molecular structure influences the biological activity of these compounds, which is crucial for optimizing their efficacy and safety.
Used in Analytical Testing and Laboratory Research:
(2-AMINO-4-CHLORO-PHENYL)-CARBAMIC ACID TERT-BUTYL ESTER also serves as a reference standard in analytical testing. It is used to ensure the accuracy and reliability of test results in laboratory research, aiding in the validation of experimental methods and the comparison of results across different studies.

Upstream product

• 24424-99-5 di-tert-butyl dicarbonate 
• 89-63-4 4-Chloro-2-nitroaniline 

Downstream Products

• 1029958-37-9 C₂₂H₂₂ClN₅O₄ 
• 1040363-36-7 tert-butyl 4-chloro-2-(1-cyclooctylpiperidin-4-ylamino)phenylcarbamate 
• 579484-37-0 8-Chloro-4-[3-(6-methyl-pyrimidin-4-yl)-phenyl]-1,3-dihydro-benzo[b][1,4]diazepin-2-one 
• 579478-02-7 (4-chloro-2-{3-[3-(2,6-dimethyl-pyridin-4-yl)-phenyl]-3-oxo-propionylamino}-phenyl)-carbamic acid tert-butyl ester 
• 579477-81-9 {4-chloro-2-[3-oxo-3-(3-pyrimidin-5-yl-phenyl)-propionylamino]-phenyl}-carbamic acid tert-butyl ester 
• 579477-59-1 (4-chloro-2-{3-[3-(2-methyl-pyridin-4-yl)-phenyl]-3-oxo-propionylamino}-phenyl)-carbamic acid tert-butyl ester 
• 579477-30-8 (4-chloro-2-{3-[3-(6-methoxy-pyridin-3-yl)-phenyl]-3-oxo-propionylamino}-phenyl)-carbamic acid tert-butyl ester 
• 579477-10-4 (4-chloro-2-{3-[3-(2-methyl-pyridin-3-yl)-phenyl]-3-oxo-propionylamino}-phenyl)-carbamic acid tert-butyl ester 
• 579484-24-5 8-Chloro-4-(3-pyrimidin-4-yl-phenyl)-1,3-dihydro-benzo[b][1,4]diazepin-2-one 
• 579477-09-1 (4-chloro-2-{3-[3-(6-methyl-pyridin-3-yl)-phenyl]-3-oxo-propionylamino}-phenyl)-carbamic acid tert-butyl ester 
• 579476-99-6 {4-chloro-2-[3-oxo-3-(3-pyridin-4-yl-phenyl)-propionylamino]-phenyl}-carbamic acid tert-butyl ester 

Relevant academic research and scientific papers

Discovery of a Selective Aurora A Kinase Inhibitor by Virtual Screening

Here we report the discovery of a selective inhibitor of Aurora A, a key regulator of cell division and potential anticancer target. We used the atom category extended ligand overlap score (xLOS), a 3D ligand-based virtual screening method recently developed in our group, to select 437 shape and pharmacophore analogs of reference kinase inhibitors. Biochemical screening uncovered two inhibitor series with scaffolds unprecedented among kinase inhibitors. One of them was successfully optimized by structure-based design to a potent Aurora A inhibitor (IC50 = 2 nM) with very high kinome selectivity for Aurora kinases. This inhibitor locks Aurora A in an inactive conformation and disrupts binding to its activator protein TPX2, which impairs Aurora A localization at the mitotic spindle and induces cell division defects. This phenotype can be rescued by inhibitor-resistant Aurora A mutants. The inhibitor furthermore does not induce Aurora B specific effects in cells.

NOVEL BENZODIAZEPINONES AS MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR FUNCTIONS AND NEUROLOGICAL USES THEREOF

The present invention relates to novel benzodiazepinone compounds of Formulae (I) wherein R1, R2, R4, R6, R7, R8, R9, and R10 are as defined herein. The invention also

2-Benzimidazolyl-9-(chroman-4-yl)-purinone derivatives as JAK3 inhibitors

A novel class of Janus tyrosine kinase 3 (JAK3) inhibitors based on a 2-benzimidazoylpurinone core structure is described. Through substitution of the benzimidazoyl moiety and optimization of the N-9 substituent of the purinone, compound 24 was identified incorporating a chroman-based functional group. Compound 24 shows excellent kinase activity, good oral bioavailability and demonstrates efficacy in an acute mechanistic mouse model through inhibition of interleukin-2 (IL-2) induced interferon-γ (INF-γ) production.

HETEROCYCLIC-SUBSTITUTED PIPERDINE COMPOUNDS AND THE USES THEREOF

The invention relates to Heterocyclic-Substituted Piperidine Compounds, compositions comprising an effective amount of a Heterocyclic-Substituted Piperidine Compound and methods to treat or prevent a condition, such as pain, comprising administering to an animal in need thereof an effective amount of a Heterocyclic-Substituted Piperidine Compound

BENZIMIDAZOLE DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF, THEIR USE AS FXR AGONISTS AND PHARMACEUTICAL PREPARATIONS CONTAINING THE SAME

The invention is concerned with novel benzimidazole derivatives of formula (I) wherein R1 to R8 are as defined in the description and in the claims, as well as physiologically acceptable salts and esters thereof. These compounds bind

COMBINATION OF MGLUR2 ANTAGONIST AND ACHE INHIBITOR FOR TREATMENT OF ACUTE AND/OR CHRONIC NEUROLOGICAL DISORDERS

The present invention relates to a method of treatment or prevention of acute and/or chronic neurological disorders, to a pharmaceutical composition comprising an inhibitor of acetylcholinesterase (AChE inhibitor) and a metabotropic Glutamate receptor 2 antagonist (mGluR2 antagonist), to the use of an AChE inhibitor and a mGluR2 antagonist in the preparation of a medicament, and. to kits comprising an AChE inhibitor and a mGluR2 antagonist.

Dihydro-benzo[b][1,4]diazepin-2-one derivatives

This invention relates to dihydro-benzo[b][1,4]diazepin-2-one derivatives of the formula wherein R1, R2, X and Y are as defined in the specification and R3 is a six-membered aromatic heterocycle containing 1 to 3 nitrogen atoms or a pyridine-N-oxide as further defined in the specification. The invention further relates to medicaments containing these compounds, a process for their preparation as well as their use for preparation of medicaments for the treatment or prevention of acute and/or chronic neurological disorders.